Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications

被引：1

作者：

Guo, Yining ^{[1
,2
]}

Wang, Xudong ^{[2
]}

Zhang, Chen ^{[2
]}

Chen, Weiwu ^{[2
]}

Fu, Yutian ^{[2
]}

Yu, Yanlan ^{[2
]}

Chen, Yicheng ^{[2
]}

Shao, Tiejuan ^{[1
]}

Zhang, Jie ^{[2
]}

Ding, Guoqing ^{[2
,3
]}

机构：

[1] Zhejiang Chinese Med Univ, Coll Basic Med Sci, Hangzhou 310053, Peoples R China

[2] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Urol, Hangzhou 310016, Peoples R China

[3] Zhejiang Univ, Sir Run Run Shaw Hosp, Natl Engn Res Ctr Innovat & Applicat Minimally Inv, Sch Med, Hangzhou 310028, Peoples R China

来源：

IMMUNOTARGETS AND THERAPY | 2025年 / 14卷

基金：

中国国家自然科学基金;

关键词：

tumor; B7-H3 (CD276); immune checkpoint; tumor immunotherapy; tumor microenvironment; GASTRIC-CANCER CELLS; CAR T-CELLS; LUNG-CANCER; EXPRESSION; MICROENVIRONMENT; METABOLISM; MOLECULE; INVASION; PROMOTES; CD276;

D O I：

10.2147/ITT.S507522

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

B7-H3 (CD276) is an immune checkpoint from the B7 family of molecules and is abnormally expressed in tumor cells as a co- inhibitory molecule to promote tumor progression. Within the tumor microenvironment (TME), B7-H3 promotes tumor progression by impairing the T cell response, driving the polarization of tumor-associated macrophages (TAMs) to M2 phenotype, and inhibiting the function of other immune cells. In addition, B7-H3 promotes tumor cell proliferation, migration, invasion, metabolism disorder, angiogenesis, and resistance to treatment to promote tumor progression through its non-immunological functions. Immunotherapy targeting B7-H3, as well as combinations with other immune checkpoint therapies, have shown certain efficacy. In this review, we synthesizes the expression of B7-H3 and its mechanism to promote tumor progression through inducing immunomodulation and non- immunological functions, as well as its role of B7-H3 in tumor therapy, aiming to provide a reference for the clinical treatment of tumors.

引用

页码：291 / 320

页数：30

共 143 条

[1] Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups [J].

Andrews, Lawrence P. ;

Yano, Hiroshi ;

Vignali, Dario A. A. .

NATURE IMMUNOLOGY, 2019, 20 (11) :1425-1434

[2]

[Anonymous], Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

[3] Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens [J].

Behan, Fiona M. ;

Iorio, Francesco ;

Picco, Gabriele ;

Goncalves, Emanuel ;

Beaver, Charlotte M. ;

Migliardi, Giorgia ;

Santos, Rita ;

Rao, Yanhua ;

Sassi, Francesco ;

Pinnelli, Marika ;

Ansari, Rizwan ;

Harper, Sarah ;

Jackson, David Adam ;

Mcrae, Rebecca ;

Pooley, Rachel ;

Wilkinson, Piers ;

van der Meer, Dieudonne ;

Dow, David ;

Buser-Doepner, Carolyn ;

Bertotti, Andrea ;

Trusolino, Livio ;

Stronach, Euan A. ;

Saez-Rodriguez, Julio ;

Yusa, Kosuke ;

Garnett, Mathew J. .

NATURE, 2019, 568 (7753) :511-+

[4] Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms [J].

Bejarano, Leire ;

Kauzlaric, Annamaria ;

Lamprou, Eleni ;

Lourenco, Joao ;

Fournier, Nadine ;

Ballabio, Michelle ;

Colotti, Roberto ;

Maas, Roeltje ;

Galland, Sabine ;

Massara, Matteo ;

Soukup, Klara ;

Lilja, Johanna ;

Brouland, Jean -Philippe ;

Hottinger, Andreas F. ;

Daniel, Roy T. ;

Hegi, Monika E. ;

Joyce, Johanna A. .

CANCER CELL, 2024, 42 (03) :378-395.e10

[5] Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma [J].

Brignole, Chiara ;

Calarco, Enzo ;

Bensa, Veronica ;

Giusto, Elena ;

Perri, Patrizia ;

Ciampi, Eleonora ;

Corrias, Maria Valeria ;

Astigiano, Simonetta ;

Cilli, Michele ;

Loo, Derik ;

Bonvini, Ezio ;

Pastorino, Fabio ;

Ponzoni, Mirco .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (09)

[6] The B7:CD28 family and friends Unraveling coinhibitory interactions [J].

Burke, Kelly P. ;

Chaudhri, Apoorvi ;

Freeman, Gordon J. ;

Sharpe, Arlene H. .

IMMUNITY, 2024, 57 (02) :223-244

[7] Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy [J].

Cai, Dongli ;

Li, Jiaming ;

Liu, Dingfeng ;

Hong, Shanjuan ;

Qiao, Qin ;

Sun, Qinli ;

Li, Pingping ;

Lyu, Nanan ;

Sun, Tiantian ;

Xie, Shan ;

Guo, Li ;

Ni, Ling ;

Jin, Liping ;

Dong, Chen .

CELLULAR & MOLECULAR IMMUNOLOGY, 2020, 17 (03) :227-236

[8] Engineering artificial non-coding RNAs for targeted protein degradation [J].

Cao, Congcong ;

Li, Aolin ;

Xu, Chaojie ;

Wu, Baorui ;

Yao, Lin ;

Liu, Yuchen .

NATURE CHEMICAL BIOLOGY, 2025, 21 (03) :393-401

[9] B7-H3:: A costimulatory molecule for T cell activation and IFN-γ production [J].

Chapoval, AI ;

Ni, J ;

Lau, JS ;

Wilcox, RA ;

Flies, DB ;

Liu, D ;

Dong, HD ;

Sica, GL ;

Zhu, GF ;

Tamada, K ;

Chen, LP .

NATURE IMMUNOLOGY, 2001, 2 (03) :269-274

[10] Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response [J].

Chen, Jung-Tsu ;

Chen, Chein-Hung ;

Ku, Ko-Li ;

Hsiao, Michael ;

Chiang, Chun-Pin ;

Hsu, Tsui-Ling ;

Chen, Min-Huey ;

Wong, Chi-Huey .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (42) :13057-13062

← 1 2 3 4 5 6 7 8 9 10 →